To assess the outcome of Intralesional triamcinolone acetonide with 5 -fluorouracil in the treatment of keloids
Not Applicable
- Conditions
- Health Condition 1: L91- Hypertrophic disorders of skin
- Registration Number
- CTRI/2023/02/049632
- Lead Sponsor
- SURYA T
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
patients with keloids
Patients who are willing to participate in the study
Exclusion Criteria
Patients below 18 years and above 60 years
Pregnancy & Lactation
Patient with comorbidities
Immunocompromised patients
History of previous treatment for keloids and infected ,ulcerated keloids
Patients allergic to triamcinolone acetonide , 5-fluorouracil ,and lignocaine
Patient not willing to participate in the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method PIGMENTATION: <br/ ><br>0 - Normal <br/ ><br>1 - Hypopigmentation <br/ ><br>2 - Mixed <br/ ><br>3 - Hyperpigmentation <br/ ><br>PLIABILITY: <br/ ><br>0 - Normal <br/ ><br>1 - Supple (flexible with minimal resistance) <br/ ><br>2 - Yielding (giving way to pressure) <br/ ><br>3 - Firm (inflexible, resistant to manual pressure) <br/ ><br>4 - Banding (rope like tissue that blanches) <br/ ><br>5 - Contracture (permanent shortening of scar producing <br/ ><br>deformity) <br/ ><br>HEIGHT: <br/ ><br>0 - Normal <br/ ><br>1 - Less than2mm <br/ ><br>2 - 2 to 5 mm <br/ ><br>3 - more than 5mmTimepoint: every 3 weeks for 18 weeks
- Secondary Outcome Measures
Name Time Method Treatment side effectsTimepoint: every 3 weeks for 18 weeks